{"name":"Aronora, Inc.","slug":"aronora-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AB002 Dose 1","genericName":"AB002 Dose 1","slug":"ab002-dose-1","indication":"Other","status":"phase_2"},{"name":"E-WE Thrombin- Dose 1","genericName":"E-WE Thrombin- Dose 1","slug":"e-we-thrombin-dose-1","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AB023- Dose 1","genericName":"AB023- Dose 1","slug":"ab023-dose-1","indication":"Relapsed or refractory chronic lymphocytic leukemia","status":"phase_2"}]}],"pipeline":[{"name":"AB002 Dose 1","genericName":"AB002 Dose 1","slug":"ab002-dose-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AB023- Dose 1","genericName":"AB023- Dose 1","slug":"ab023-dose-1","phase":"phase_2","mechanism":"AB023 is a small molecule that targets the PI3K delta subunit.","indications":["Relapsed or refractory chronic lymphocytic leukemia","Relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"E-WE Thrombin- Dose 1","genericName":"E-WE Thrombin- Dose 1","slug":"e-we-thrombin-dose-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5YemxlLTJxbVEyTEdWT3hfZXZRdzNJOWI3cGV0MmhYLXI3NUJ6MmdsWE1kQXFRXzJIU0l3UjViN2pFOS1FTWFZWHZZZDdBU19QS3BCTkRCNWxPVmpMcUo4?oc=5","date":"2024-07-26","type":"trial","source":"nature.com","summary":"Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial | Communications Medicine - nature.com","headline":"Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomiz","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQYXNRVC11Wm1fekdWSUZyWS1Db21QLWd0OWVfd0NmTHJiaUE1a1pDRHlxSlRqV1N6SDRUUXlsd3U1WUR4WjZuTWZwWjhOaUt1S1lRZnk1UmJCNEVqbGJlbDZqX3RZWGNydVhhRXotdDNsSTB4VEkxZC1nY21vcm10WS03UWg3dlkzWFhlTnBFbFl6MElnYzR1THRSNkhMeElITDhKM2ZtcjRBUQ?oc=5","date":"2023-10-13","type":"pipeline","source":"The Business Journals","summary":"Aronora raises funding round to support clot-buster drug development - The Business Journals","headline":"Aronora raises funding round to support clot-buster drug development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxORHo3b1RyR2ExWV9CUk1XSmxQczBOekE1YklFY2hPa1BlTTZZaVN3MExzVXNfQjl0dTFkQmRuSHBYb2psSGFtYzlpbEJYRmVXeWhidU50WnB0TnpNX25HOFYxa1JVeHVFYnpFQUhGdnFpUTJJenFPMVlzV0taR01iQkJUaDNRbmJCcWExY1pyUlc4cjg3Y2RRM1BSN2dGSmdVeDlNSGFwbVhrSzQzRk0zY1VwZmpkUVY5NndWN0ZOUDhUanJRcEFLTzA0djlPVWF0T3lFUkFEZGlvWnp6Y1BR?oc=5","date":"2021-07-19","type":"trial","source":"PR Newswire","summary":"Aronora Reports Positive Topline Data From Phase 2 Study of AB023 in Hemodialysis Patients - PR Newswire","headline":"Aronora Reports Positive Topline Data From Phase 2 Study of AB023 in Hemodialysis Patients","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPNFRnU25oeWkzWlpsSXBzTTZBQ1l4WjZXZlJrYzBzZlNGUmsxcGFJNWVBSUJ4ZFNxeXBSQUprejFsUnNQT19ERFJHVmlJWXpPU1UwWmgtY0x2WE1sZnRUNUN1Yzh6MHlzbWd0TnNzVDd3bEVXTUd4bTF5MGpWOXlqanNpUmhLSFd1TlV3VVliWVN6TzktcDFsaXhiM0VHTXhUXzdEa0NEVjZiV0U1WV9tTUc0Q0VaUnE5X21kVUY0MkJaNURCSEltZ2puRWkzaDd3cXBobVBnTnc0Vk51eWowNC1TT3c1a0RoQUZHSGU0XzhhWXM?oc=5","date":"2020-12-02","type":"regulatory","source":"PR Newswire","summary":"Aronora Announces Clinical Data to Be Presented at the 62nd American Society of Hematology Annual Meeting - PR Newswire","headline":"Aronora Announces Clinical Data to Be Presented at the 62nd American Society of Hematology Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOM1BlcHBWaHJoemRJRFljeDZYc2RQVEZ2Wm5jNzlXWEVlQlE1bVY5cUc4aHFjNnl4SUpuVUNCbGxhcVV1MUMtdS0yVHpMWWo0M19tM1lLZmFIVFBqV2VJYTAtRWpESmV2Wk9vQzJ0d0JfTzlFYmJpcWo2QUJjNG4zOWV1YUYwQmc0bHcyVkJYdlplaHZJN3IwT2NCMVhnNkJacHp3VUlXaERvdw?oc=5","date":"2017-09-07","type":"pipeline","source":"The Business Journals","summary":"Portland biotech startup may have the remedy for blood clots - The Business Journals","headline":"Portland biotech startup may have the remedy for blood clots","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}